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Abstract
B cells play diverse and fundamental roles in the pathogenesis of
autoimmune diseases. Consequently, therapeutic targeting of B
cells is gaining prominence in our clinical armamentarium for an ever
expanding array of autoimmune and neoplastic disorders. Therefore,
it is of great importance to understand the mechanism of action of B
cell depletion. Given that the ideal consequence of B cell depletion
would be the subsequent re-establishment of immunologic
tolerance, a detailed analysis of the properties of the emerging
repertoire will be required. The results presented by Rouzière and
coworkers in their study of rheumatoid arthritis patients shed some
light on this question and are discussed in this commentary.
As reflected in the work by Rouzière and coworkers [1], B
cells have become a major therapeutic target for autoimmune
diseases. This prominence stems from two convergent develop-
ments. One of these is the understanding that, in addition to
conventional antibody dependent effects, B cells also play
important regulatory and potentially pathogenic roles through
antibody independent mechanisms, including antigen presenta-
tion, T cell activation and polarization, dendritic cell regulation,
and cytokine and chemokine production [2]. Moreover,
mounting clinical evidence strongly supports the therapeutic
benefit of targeting B cells in an array of autoimmune
conditions ranging from systemic lupus erhthematosus (SLE)
to rheumatoid arthritis (RA) and Wegener’s granulomatosis [3].
These findings raise a number of important questions that
remain to be formally addressed. Such questions pertain to
the specific pathogenic roles of B cells in different diseases,
the different mechanisms whereby B cell depletion may
improve disease, the relative sensitivity of different B cell
subsets to depleting agents, and the kinetics, magnitude and
quality of B cell repopulation. The latter issue is of central
importance and is the focus of the article by Rouzière and
coworkers [1]. Indeed, the breakdown of B cell tolerance for
autoantigens may be at the core of the pathogenesis of SLE
and RA and perhaps of other autoimmune diseases.
As is always the case with disease, the ultimate goal is to
achieve cure and inevitably the elusive question of whether B
cell tolerance can be restored must be asked. In order for this
to be possible one must postulate that tolerance breakdown
and the selection of a pathogenic repertoire is the result of
environmental hits on a stochastically generated B cell
repertoire in a genetically predisposed individual. On that
basis, it is apparent that, given a second chance, the B cell
repertoire could become a good citizen either by escaping
harmful environmental influences and/or by sheer good luck
in the stochastic generation of immunologic diversity.
Furthermore, the prolonged ‘absence’ of B cells could also
have important influences on the T cell repertoire either by
decreasing T cell activation or by shifting T-helper cell
polarization, presumably favoring a T-helper-1 profile [4,5].
Answering or even addressing this question in human studies
is a tall order. In order to do so, formal testing of the antigenic
reactivity of the emerging repertoire will ultimately be required.
This approach will determine whether immature autoreactive B
cells are appropriately purged or edited. Furthermore, given
that even healthy individuals still bear a large load of
autoreactive B cells in the mature compartment, it will also be
important to achieve a phenotypic and functional definition of
anergy to elucidate whether the newly developed mature B
cells are being appropriately silenced [6,7].
Although the information obtained by Rouzière and coworkers
[1] does not clarify these issues, it offers a molecular glimpse
into the reconstitution of the heavy chain B cell repertoire in
two patients with RA treated with rituximab, whose peripheral
blood was analyzed before treatment and at different time
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points after treatment. Some limitations of the work should be
borne in mind, prominently the small number of patients studied
and the nonquantitative nature of the bulk PCR approach
employed by the investigators. Furthermore, for most of the
study total B cells were studied without differentiating specific
B cell subsets. This situation was corrected for by confirmation
of somatic hypermutation in which single cell PCR analysis of
VH genes was used and B cells were separated into a
CD19+CD27– fraction (which conventionally would include
immature, transitional, and mature naïve B cells) and a
CD19+CD27+ fraction (which would include both isotype
switched and nonswitched memory B cells).
Unfortunately, the single cell PCR experiments did not
discriminate between IgM and IgG sequences and suffered
from a relatively small sample size. Nevertheless, the central
finding that the ‘early’ (7 months) repopulating repertoire
contained a substantial amount of somatic hypermutation that
was significantly higher than before treatment only to decline
again over time is tantalizing, and there are several potential
explanations for this. As pointed out by the investigators, it
seems likely that this finding may reflect initial expansion of
residual memory cells. Whether this is indeed the case could
be explored by analysis of residual B cells at earlier points
after treatment. In fact, in SLE patients we showed that, even
in those with ‘complete’ peripheral B cell depletion, it is
possible to detect residual B cells that predominantly express
a switched memory phenotype [8]. The expansion of residual
B cells could be favored by a lymphopenic environment and
lack of competition for survival factors such as BlyS. It would
also be important to determine whether the surviving memory
cells are enriched for autoreactivity.
A surprising and provocative aspect of the study by Rouzière
and coworkers [1] is the finding that even CD27– B cells
exhibited a level of somatic hypermutation that was
substantially higher than expected for either naïve or
immature/transitional B cells, and that was more in accord
with the levels expressed by memory cells. An explanation for
this could be that these cells represent a subset of memory
cells lacking CD27, as suggested by the authors. Interestingly,
however, published and unpublished data indicate that such a
population may be greatly increased in patients with active
SLE but not in patients with RA [8,9]. Furthermore, at least in
SLE, such cells are highly sensitive to rituximab and do not
appear to be preferentially expanded after treatment. An
alternative, not mutually exclusive explanation is that the
mutated CD27– B cells could represent an expansion of
marginal zone B cells – a compartment whose expansion has
been implicated in the pathogenesis of autoimmune diseases
and that in humans predominantly contains CD27+ memory
cells. It has been shown that in children younger than 2 years
marginal zone B cells undergo somatic hypermutation of their
antibody genes early in ontogeny [10]. Although in that study
the B cells analyzed expressed CD27, it is tempting to
postulate that upon profound B cell depletion there could be a
re-enactment of early B cell ontogeny and that the cells
described in the report by Rouzière and coworkers [1] might
represent mutated marginal zone B cell precursors that have
not yet acquired CD27. Elucidation of this interesting question
will undoubtedly require fine discrimination and separate
analysis of B cell subsets in patients treated with rituximab.
Conclusion
It is safe to expect that even in patients with good clinical B
cell depletion some B cells will survive and may experience
preferential early expansion in a lymphopenic environment.
Ultimately, the quality of the emerging repertoire will depend
to a large extent on the interplay and competition between
these cells and newly generated B cells. The growing
availability of patients treated with B cell depletion should
allow investigators to understand the determinants that
underlie B cell reconstitution in different autoimmune
diseases and in individual patients. The knowledge gained
from such studies should greatly enhance our ability to treat
these diseases and tailor therapy for individual cases. In
addition, they should contribute to our understanding of basic
aspects of B cell biology and homeostasis.
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